Efficacy and Safety of Telitacicept Combined With Baricitinib for Refractory Rheumatoid Arthritis

Who May Qualify: - 1\. Age 18-85 years - 2\. Diagnosed with refractory rheumatoid arthritis according to the 2021 EULAR (European Alliance of Associations for Rheumatology) diagnostic criteria - 3\. The traditional disease-improving rheumatic drug treatment is ineffective, and the use of two or more biological/targeted disease improving anti-rheumatic drugs is ineffective, and telitacicept combined with tofacitinib is required treated patients - 4\. Voluntarily provided written willing to sign a consent form Who Should NOT Join This Trial: - 1\. Exclusion of patients with severe diseases of major organs (e.g., heart, liver, or lungs) - 2\. Patients with malignancies, hematological disorders, or other autoimmune conditions (where your immune system attacks your own body)s (excluding rheumatoid arthritis) - 3\. History of allergy/hypersensitivity to the study medications (Telitacicept or Tofacitinib) - 4\. Active tuberculosis or active infectious diseases requiring systemic treatment - 5\. Pregnancy, lactation, or refusal to use contraception during the study - 6\. Failure to complete the prescribed Telitacicept + Tofacitinib regimen due - to:Non-adherence or Severe adverse reactions - 7\. Other conditions contraindicating participation per investigator judgment Always talk to your doctor about whether this trial is right for you.